Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Humby, Frances; Durez, Patrick; H Buch, Maya; J Lewis, Myles; Rizvi, Hasan; Rivellese, Felice; Nerviani, Alessandra; Giorli, Giovanni; Mahto, Arti; Montecucco, Carlomaurizio; Lauwerys, Bernard; Ng, Nora; Ho, Pauline; Bombardieri, Michele; C Romão, Vasco; Verschueren, Patrick; Kelly, Stephen; Paolo Sainaghi, Pier; Gendi, Nagui; Dasgupta, Bhaskar; Cauli, Alberto; Reynolds, Piero; D Cañete, Juan; Moots, Robert; C Taylor, Peter; J Edwards, Christopher; Isaacs, John; Sasieni, Peter; Choy, Ernest; Pitzalis., Costantino